Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: About RAV's
Tig


Admin

Status: Offline
Posts: 8614
Date:
RE: About RAV's
Permalink  
 


Hoodie, 

You‘re correct, RAV = Resistance Associated Variant. You will slso see it referred to as an RAS, which is Resitance Associate Substitution. They mean the same thing. 

Here‘s a discussion we had on the topic. There is a lot of information here on the forum if you search RAV and RAS. There can be variants at many locations on the DNA

RAV/RAS 

HCV Inhibitors  (Dated and technical, but informative)



__________________

Tig

62 yo GT1A - 5 Mil - A2/F3 - (1996) Intron A - Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 1-4 years!

Hep C FAQ   Lab Ref. Ranges

Signature Line Set Up/Abbreviations   Payment Assistance

 



Senior Member

Status: Offline
Posts: 338
Date:
Permalink  
 

Canuck, Sorry if I missed it in your post but what are RAVs?

Many thanks in advance, hoodie

Edited to add: oh it must be resistance variants or Resistance to Anti Virals yeah? I feel really bad for people who have RAVs. Will pray for them.



-- Edited by Hoodietree on Sunday 18th of November 2018 10:41:31 AM

__________________

F, 51, GT3, HCV since 1989, no alcohol since 1999, Fibrosis score F0-1 (.36), VL 216,000, ALT 23, AST 26, Epclusa SOT 7/26/18 EOT 10/18/18. Thank you God. 



Guru

Status: Offline
Posts: 2970
Date:
Permalink  
 

Another article/data presentation about NS5A RAV's (coming out of the current Liver Meeting going on). Interesting (to me). I don't pretend to understand all of this nor the wideness of the ramifications, but it's interesting all the same, noting it IS "Japan" data-heavy, and that it is also drug-heavy limited to the combo Daclatasvir/Asunaprevir (DCV/ASV) - a NS5A and a NS3/4 respectively, as well as being Harvoni retreatment drug-heavy info - about those who failed Asun/Dacla treatment in Japan, and, their further outcomes when they they (and their acquired RAV's) were subsequently re-treated with Harvoni (a NS5A and NS5B combo) - all of this info (on their NS5A RAV's and outcomes) just reinforces prior data on the negative importance of anyone owning Y93, L31 (and other) RAV's.

Nice, the tidbit at the end, that aside from it being a good thing to be a women (if you want to hedge your bets), that generally, it also pays (duh) not to have any RAV's the first place when being re-treated with Ledi. wink 

 

MEETING NEWS - (from the current Liver Meeting going on right now)

NS5A substitutions affect early HCV treatment failures, retreatment

 


__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 63 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)

Tig


Admin

Status: Offline
Posts: 8614
Date:
Permalink  
 

Interesting to see it laid out in that fashion. They should make these things easier to understand! I guess they weren't considering us when they developed the data presentation. We'll have a talk with them about that! In the meantime, I'll be putting cold towels on my head to keep things from overheating, whew!

Thanks for the information. When I was on treatment, I was considered fortunate to have access to a single NS3 - Boceprevir, but it did the trick. With the new NS 5a/b combos, along with the new NS3/4a's, it's no wonder we're seeing such high rates of success. These triples are hard for HCV to argue with! The breakthroughs are coming fast, but I have to wonder how many more they'll come up with. Lets keep our fingers crossed on that!



__________________

Tig

62 yo GT1A - 5 Mil - A2/F3 - (1996) Intron A - Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 1-4 years!

Hep C FAQ   Lab Ref. Ranges

Signature Line Set Up/Abbreviations   Payment Assistance

 



Guru

Status: Offline
Posts: 2970
Date:
Permalink  
 

About RAV's - (not very layman-friendly info)

Roughly from 2016, so, not very current, so of course, little mention of newer drugs that have just come to the fore or are coming to the fore, such as Glilead's Epclusa/Vosevi, Abb Vie's Maviret, Jansen products and Merck's newer combos - various good combos/doublets and triplets, most of these companies now offering new NS5A's, NS5B's and new 3/4A's. (Many of the newer 5A and 5B drugs will not be mentioned here in these reviews, nor will newer 3/4A's like Vox, Grazo and Glec). Basically, all the newest drugs that are working so well for folks with RAV's. But - you can still glean other small important things from these stats - incorrect genotyping is possible, how common (baseline) treatment-naive RAVs can be, the importance of how many fold the resistance is, common tactics that have been used in the past to ensure the greatest success, and in general how successful treatment has become nowadays, despite coming to first treatment with undefined RAV's, or when coming to re-treatment with known RAV's.

Country heavy data - Japan - for first one.

http://congress-ph.ru/common/htdocs/upload/fm/gepatology/2016/prez/2-5-3-e.pdf

Country heavy data - Italy - for second one.

http://regist2.virology-education.com/2016/14EU/25_Cento.pdf

 

 

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 63 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.